Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0GMWTW)
| ADC Name |
BL-M24D1
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BL-M24D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Biokin Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
WA-00
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | |||||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
4 Trials
|
||||||||
| Multiple myeloma |
1 Trials
|
||||||||
| Unspecific hematological malignancies |
1 Trials
|
||||||||
| Lung cancer |
2 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|